Payment overview · 2025
General Payments
$457.59
24 reported records · 14 companies
Healthcare provider profile · identity verified
Anne T Donovan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WALTON, KY · NPI 1124061981
Verified facts
What the public records show
CMS Open Payments records show Anne T Donovan, M.D. received $457.59 in general payments during 2025 across 24 reported records.
Vanda Pharmaceuticals Inc. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.22 | 17.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.11 | 17.1% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $54.77 | 12.0% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $45.43 | 9.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.80 | 7.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.65 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.13 | 4.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.75 | 4.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $17.66 | 3.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.29 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.11 | 3.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.07 | 3.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.91 | 3.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.69 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $457.59 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $79.22 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $79.22 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $54.77 | 3 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $50.72 | 3 | 2025 |
Source payment records
|
|||||
| LITFULO Normalized: litfulo |
Drug | PFIZER INC. | $50.72 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $45.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $33.44 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 754 | 214 |
| Lisinopril | Lisinopril | 492 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 112 |
| Omeprazole | Omeprazole | 312 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 67 |
| Metformin Hcl | Metformin Hcl | 203 | 57 |
| Losartan Potassium | Losartan Potassium | 201 | 66 |
| Methylprednisolone | Methylprednisolone | 200 | 160 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 56 |
| Potassium Chloride | Potassium Chloride | 162 | 58 |
| Alendronate Sodium | Alendronate Sodium | 148 | 42 |
| Gabapentin | Gabapentin | 137 | 39 |
| Tramadol Hcl | Tramadol Hcl | 132 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 37 |
| Furosemide | Furosemide | 123 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 37 |
| Buspirone Hcl | Buspirone Hcl | 117 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 37 |
| Azithromycin | Azithromycin | 112 | 96 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 31 |
| Trazodone Hcl | Trazodone Hcl | 95 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 29 |
| Carvedilol | Carvedilol | 92 | 22 |
| Sertraline Hcl | Sertraline Hcl | 90 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 70 |
| Bupropion Xl | Bupropion Hcl | 81 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 26 |
| Lovastatin | Lovastatin | 73 | 19 |
| Allopurinol | Allopurinol | 70 | 19 |
| Ozempic | Semaglutide | 69 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 19 |
| Ezetimibe | Ezetimibe | 67 | 22 |
| Glipizide | Glipizide | 67 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | 19 |
| Nystatin | Nystatin | 64 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 13 |
| Simvastatin | Simvastatin | 58 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 18 |
| Baclofen | Baclofen | 50 | 12 |
| Atenolol | Atenolol | 49 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 11 |
| Metformin Hcl Er | Metformin Hcl | 48 | 13 |
| Finasteride | Finasteride | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 32 |
| Meloxicam | Meloxicam | 46 | 17 |
| Montelukast Sodium | Montelukast Sodium | 46 | 13 |
| Valsartan | Valsartan | 45 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 16 |
| Jardiance | Empagliflozin | 42 | 16 |
| Levemir Flexpen | Insulin Detemir | 42 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 40 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 12 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 13 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 30 |
| Klor-Con M20 | Potassium Chloride | 32 | 13 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 19 |
| Victoza 3-Pak | Liraglutide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 18 |
| Cefuroxime | Cefuroxime Axetil | 22 | 21 |
| Fluconazole | Fluconazole | 22 | 15 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Prednisone | Prednisone | 19 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 16 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,sf,0.3ml | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Chlordiazepoxide-Amitriptyline | Amitriptyline/Chlordiazepoxide | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $457.59 · 24 records | Vanda Pharmaceuticals Inc. | ABRYSVO, CAPLYTA, CIBINQO, COMIRNATY, FANAPT, FREESTYLE LIBRE 3, HETLIOZ, Heplisav-B, INGREZZA, LITFULO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, Sunosi, UBRELVY, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error